6d) Another immunotherapeutic treatment option for R/R #FL is with chimeric antigen receptor T cells (#CAR_T). Specifically, #axicabtagene ciloleucel (axi-cel) is #FDA-approved for this indication, based on results of the #ZUMA-5 trial. See https://t.co…
Axicabtagene ciloleucel in relapsed or refractory indolent NHL (ZUMA-5): a multi center, phase 2 trial - Axicabtagene ciloleucel showed high rates of durable responses and had a manageable safety profile in patients with R/R indolent NHL https:/…
RT @TheLancetOncol: Also in the Jan issue: phase 2 ZUMA-5 trial - #Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin #…
Also in the Jan issue: phase 2 ZUMA-5 trial - #Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin #lymphoma #CARTcell #lymsm https://t.co/igiMc593Gf